Fidelity Biosciences - Andrew Hedin

Stephen Knight, M.D.
Robert Weisskoff, Ph.D.
Hingge Hsu, M.D.
Mary Bevelock Pendergast
Ben Auspitz
Thomas R. Beck, M.D.
Wei Li, Ph.D.
Jon Lim
Alex Pasteur, Ph.D.
Ketan Patel, M.D.
Jim Case
Melissa Packard
Eric Golding, M.D.
Lihan Sun, Ph.D.
Andrew Hedin
Carl Byers
Declan Doogan, M.D.
Jim Dougherty
Baruch Harris, Ph.D.

1 Main Street, 13th Floor
Cambridge, MA 02142

phone: +1 617 231 2400

fax: +1 617 231 2425

Andrew Hedin

Senior Analyst

Andrew Hedin joined Fidelity Biosciences in 2010. Prior to Fidelity Biosciences, Mr. Hedin was an Associate at Leerink Swann in the strategy consulting division. At Leerink, Mr. Hedin advised pharmaceutical, biotech and medical device clients, with engagements focused on M&A strategy, due diligence, commercial opportunity assessments, clinical development strategy, product life cycle management, and competitive landscape analysis. His case work covered a variety of therapeutic areas, including neurology, oncology, cardiology, endocrinology and rheumatology.

Mr. Hedin is a graduate of the University of Pennsylvania, where he received his B.A. in Biological Basis of Behavior. While at Penn, he conducted research in the neuroscience department and also worked for the Penn Resiliency Project, an international NIMH-funded study.